BRIEF

on SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma Names Tobias Erfurth as New Head of Investor Relations

SCHOTT Pharma AG & Co. KGaA announced the appointment of Tobias Erfurth as Head of Investor Relations, effective from August 2024. Tobias Erfurth will report directly to CFO Almuth Steinkühler and focus on strengthening the investor relations team.

Bringing over two decades of experience in finance, capital markets, and investor relations, Erfurth has notably led investor relations at Symrise AG for 13 years, aiding its growth into a DAX40 company. His prior role at Dresdner Bank and experiences surrounding the IPO of Crop Energies AG further underline his expertise.

CFO Almuth Steinkühler commented on the appointment, emphasizing Erfurth's substantial experience and potential to enhance SCHOTT Pharma's financial profile and market presence. Erfurth expressed enthusiasm about joining SCHOTT Pharma and contributing to its ongoing success in the pharmaceutical industry.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SCHOTT Pharma AG & Co. KGaA news